Organically Grown Food Not Nutritionally Better Than Conventionally Grown

Many of us go off to the grocery store and willing spend much more money for organically grown food thinking that the nutritional value of this food will be better. A recent review of the literature calls this assumption into question. The study published July 29 in The American Journal of Clinical Nutrition says there [...]

That Toxic Word – Cancer

The word “cancer” still makes most people run for cover and shrink in terror, despite the fact that there are so many cancer survivors. This word cancer remains so emotionally laden that many of the most compassionate people I know still struggle not to overtly shrink and hide from us survivors. People feel awkward and [...]

ADT2 Shows Survival Advantage Over ADT 1

Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan has released some very significant survival data about a previously reported, double-blind, randomized, multicenter phase 3 trial. This trial compared combined androgen blockade [...]

Some Findings From The Early Study of Provenge in Men with Early Stage Recurrent Prostate Cancer

There was just a release of some of the data from the on-going review sipuleucel-T, or Provenge, in men with early stage recurrent prostate cancer who have a rising serum prostate specific antigen (PSA) level, but who have not yet developed metastatic prostate cancer. The data wes presented by Oregon Health & Realm University Cancer [...]

CB7630 (Abiraterone Acetate) to Enter Phase III Trial

There is some good news on the horizon, or at least we are setting up for the possibility of some future good news. Coming off of the recent news about the very successful phase II trial of CB7630 (abiraterone acetate), Cougar Biotechnology, Inc. has reached agreement with the FDA under a special protocol assessment (SPA) [...]

Go to Top